Emmanuel Mignot Selected Research

Sleep Wake Disorders

1/2022	Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
10/2020	Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines.
1/2019	HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy.
11/2017	Autoimmunity in narcolepsy.
8/2017	Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.
7/2013	Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.
1/2013	Genome-wide association study of HLA-DQB1*06:02 negative essential hypersomnia.
4/2012	DQB1*06:02 allele-specific expression varies by allelic dosage, not narcolepsy status.
10/2009	Modafinil and γ-hydroxybutyrate have sleep state-specific pharmacological actions on hypocretin-1 physiology in a primate model of human sleep.
1/2009	IGFBP3 colocalizes with and regulates hypocretin (orexin).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emmanuel Mignot Research Topics

Disease

110	Narcolepsy 01/2022 - 02/2000
52	Cataplexy 01/2022 - 02/2000
24	Disorders of Excessive Somnolence (Hypersomnia) 01/2021 - 10/2002
22	Sleep Wake Disorders 01/2022 - 01/2002
10	Sleepiness 01/2022 - 05/2003
9	Sleep Apnea Syndromes (Sleep Apnea) 01/2021 - 12/2004
8	Sleep Deprivation 01/2021 - 01/2004
7	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022 - 10/2002
7	Human Influenza (Influenza) 10/2020 - 10/2013
5	Idiopathic Hypersomnia 01/2022 - 01/2007
4	Obstructive Sleep Apnea 11/2021 - 10/2002
4	Inflammation (Inflammations) 08/2017 - 08/2006
4	Nervous System Diseases (Neurological Disorders) 04/2014 - 10/2002
4	Insulin Resistance 01/2011 - 08/2007
3	Glioma (Gliomas) 01/2022 - 01/2021
3	Apnea 01/2021 - 11/2017
3	Infections 10/2020 - 12/2011
3	Autoimmune Diseases (Autoimmune Disease) 07/2020 - 06/2013
3	Hypertension (High Blood Pressure) 11/2017 - 12/2004
2	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 10/2021 - 01/2021
2	Parkinson Disease (Parkinson's Disease) 09/2021 - 10/2002
2	Genetic Predisposition to Disease (Genetic Predisposition) 07/2020 - 01/2004
2	Schizophrenia (Dementia Praecox) 10/2019 - 05/2002
2	Disease Susceptibility (Diathesis) 01/2015 - 02/2006
2	Obesity 02/2013 - 12/2004
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2011 - 11/2009
2	Multiple Sclerosis 03/2007 - 01/2004
2	Dementia (Dementias) 12/2004 - 01/2004
2	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 06/2003 - 10/2002
1	Death (Near-Death Experience) 01/2022
1	Encephalitis (Encephalitis, Rasmussen) 01/2022
1	Leukocytosis (Pleocytosis) 10/2021
1	Airway Obstruction (Choking) 11/2020
1	Central Sleep Apnea (Central Sleep Apnea Syndrome) 11/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2020

Drug/Important Bio-Agent (IBA)

88	OrexinsIBA 01/2022 - 01/2002
22	HLA-DQB1 antigen (HLA DQB1)IBA 01/2022 - 10/2002
11	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2007
10	NeuropeptidesIBA 12/2013 - 11/2002
9	Sodium Oxybate (gamma Hydroxybutyrate)FDA Link 01/2022 - 11/2004
9	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2011
7	AntibodiesIBA 10/2021 - 08/2009
6	Biological ProductsIBA 01/2022 - 10/2002
5	VaccinesIBA 10/2020 - 10/2013
5	Antidepressive Agents (Antidepressants)IBA 04/2016 - 02/2000
5	Neurotransmitter Agents (Neurotransmitter)IBA 06/2005 - 01/2002
4	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2003
4	Influenza Vaccines (Influenza Vaccine)FDA Link 10/2020 - 12/2013
4	pandemrixIBA 10/2020 - 10/2013
4	HLA-DQ Antigens (HLA-DQ)IBA 01/2015 - 10/2002
4	Histamine (Histamine Dihydrochloride)FDA Link 12/2013 - 11/2002
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2013 - 06/2009
4	AutoantibodiesIBA 06/2013 - 01/2009
4	HLA-DRB1 Chains (HLA DRB1)IBA 11/2008 - 01/2004
4	Orexin ReceptorsIBA 08/2008 - 06/2004
3	Leucine (L-Leucine)FDA Link 01/2022 - 01/2021
3	Pharmaceutical PreparationsIBA 11/2021 - 05/2014
3	AntigensIBA 09/2021 - 03/2007
3	Oxygen (Dioxygen)IBA 01/2021 - 11/2017
3	arepanrixIBA 10/2020 - 07/2015
3	C-Reactive ProteinIBA 11/2015 - 08/2006
3	HLA-DQA1 antigen (HLA DQA1)IBA 01/2015 - 12/2013
3	Purinergic Receptors (Receptors, Purine)IBA 10/2013 - 01/2011
3	Cathepsin HIBA 10/2013 - 01/2013
3	HDL CholesterolIBA 02/2013 - 08/2007
3	Modafinil (Provigil)FDA Link 04/2012 - 07/2006
3	Insulin (Novolin)FDA Link 01/2011 - 11/2009
3	streptolysin OIBA 09/2010 - 08/2009
3	LigandsIBA 08/2008 - 06/2004
3	LeptinIBA 10/2007 - 01/2003
2	SolutionsIBA 01/2022 - 01/2018
2	Hemagglutinins (Hemagglutinin)IBA 10/2020 - 01/2019
2	MethyltransferasesIBA 01/2020 - 10/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 10/2013
2	Peptides (Polypeptides)IBA 01/2019 - 12/2011
2	Hypnotics and Sedatives (Sedatives)IBA 04/2016 - 07/2006
2	CytokinesIBA 10/2015 - 08/2015
2	EpitopesIBA 07/2014 - 12/2013
2	Apolipoproteins E (ApoE)IBA 06/2013 - 02/2006
2	ApolipoproteinsIBA 06/2013 - 02/2006
2	Intravenous Immunoglobulins (IVIG)FDA Link 07/2012 - 10/2008
2	deoxyribonuclease BIBA 09/2010 - 08/2009
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2007 - 12/2004
2	Amphetamine (Amfetamine)FDA LinkGeneric 07/2006 - 06/2005
2	Dopamine (Intropin)FDA LinkGeneric 06/2004 - 11/2002
1	Orexin Receptor AntagonistsIBA 01/2022
1	daridorexantIBA 01/2022
1	Oligoclonal BandsIBA 10/2021
1	adenylate kinase 5IBA 10/2021
1	HLA-DRB1*07 antigenIBA 01/2021
1	Neuraminidase (Sialidase)IBA 10/2020
1	NucleoproteinsIBA 10/2020
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 07/2020
1	purineIBA 01/2020
1	Arginine (L-Arginine)FDA Link 01/2020
1	Natalizumab (Tysabri)FDA Link 01/2020
1	Glutamic Acid (Glutamate)FDA Link 01/2020

Therapy/Procedure

6	Therapeutics 09/2014 - 07/2004
1	Immunotherapy 10/2021